French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a phase 3 trial of its sickle cell disease (SCD) therapy mitapivat, sending ...

Despite missing a key endpoint, there's still likely to be value in mitapavit. Management plans for a marketing application early in 2026. The trial was designed with two primary endpoints, and it hit ...

While mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance. 40.6% of ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...

Agios Pharmaceuticals (AGIO) caught investors’ attention recently after posting a strong quarter of annual revenue growth and improved net income metrics. The company’s progress highlights its efforts ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Investing.com - Agios Pharmaceuticals (NASDAQ:AGIO), a biotech company currently trading at $35.28 with a market cap of $2.05 billion, has announced that the U.S. Food and Drug Administration (FDA) ...

The stock of Agios Pharmaceuticals is down some 40% since I last looked at this commercial-stage biotech concern in December. The company's flagship product is already FDA approved for one indication ...

Agios Pharmaceuticals (NASDAQ:AGIO) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

CAMBRIDGE, MA – Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a biopharmaceutical company focused on cellular metabolism to treat cancer and rare genetic diseases, announced the upcoming departure of a ...

8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...